Abstract
Results from the phase III TH3RESA study show that T-DM1 is effective in patients with metastatic HER2-positive breast cancer that has progressed despite two or more HER2-targeted therapies, extending their median overall survival by nearly 7 months.
©2015 American Association for Cancer Research.
MeSH terms
-
Ado-Trastuzumab Emtansine
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics
-
Breast Neoplasms / mortality*
-
Clinical Trials, Phase III as Topic
-
Female
-
Humans
-
Maytansine / analogs & derivatives*
-
Maytansine / therapeutic use
-
Mutation
-
Receptor, ErbB-2 / genetics*
-
Survival Analysis
-
Trastuzumab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Maytansine
-
ERBB2 protein, human
-
Receptor, ErbB-2
-
Trastuzumab
-
Ado-Trastuzumab Emtansine